|
1
|
Cazares LH, Drake RR, Esquela-Kirscher A,
Lance RS, Semmes OJ and Troyer DA: Molecular pathology of prostate
cancer. Cancer Biomark. 9:441–459. 2010.
|
|
2
|
Foley R, Hollywood D and Lawler M:
Molecular pathology of prostate cancer: the key to identifying new
biomarkers of disease. Endocr Relat Cancer. 11:477–488. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shen MM and Abate-Shen C: Molecular
genetics of prostate cancer: new prospects for old challenges.
Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tam L, McGlynn LM, Traynor P, Mukherjee R,
Bartlett JM and Edwards J: Expression levels of the JAK/STAT
pathway in the transition from hormone-sensitive to
hormone-refractory prostate cancer. Br J Cancer. 97:378–383. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chun JY, Nadiminty N, Dutt S, Lou W, Yang
JC, Kung HJ, et al: Interleukin-6 regulates androgen synthesis in
prostate cancer cells. Clin Cancer Res. 15:4815–4822. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Germain D and Frank DA: Targeting the
cytoplasmic and nuclear functions of signal transducers and
activators of transcription 3 for cancer therapy. Clin Cancer Res.
13:5665–5669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Constantinescu SN, Girardot M and Pecquet
C: Mining for JAK-STAT mutations in cancer. Trends Biochem Sci.
33:122–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barton BE, Karras JG, Murphy TF, Barton A
and Huang HF: Signal transducer and activator of transcription 3
(STAT3) activation in prostate cancer: Direct STAT3 inhibition
induces apoptosis in prostate cancer lines. Mol Cancer Ther.
3:11–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Agarwal C, Tyagi A, Kaur M and Agarwal R:
Silibinin inhibits constitutive activation of Stat3, and causes
caspase activation and apoptotic death of human prostate carcinoma
DU145 cells. Carcinogenesis. 28:1463–1470. 2007. View Article : Google Scholar
|
|
10
|
Samanta AK, Lin H, Sun T, Kantarjian H and
Arlinghaus RB: Janus kinase 2: a critical target in chronic
myelogenous leukemia. Cancer Res. 66:6468–6472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuke H, Shiraki K, Sugimoto K, Tanaka J,
Beppu T, Yoneda K, et al: Jak inhibitor induces S phase cell-cycle
arrest and augments TRAIL-induced apoptosis in human hepatocellular
carcinoma cells. Biochem Biophys Res Commun. 363:738–744. 2007.
View Article : Google Scholar
|
|
12
|
Seo IA, Lee HK, Shin YK, Lee SH, Seo SY,
Park JW and Park HT: Janus Kinase 2 Inhibitor AG490 Inhibits the
STAT3 Signaling Pathway by Suppressing Protein Translation of
gp130. Korean J Physiol Pharmacol. 13:131–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shodeinde AL and Barton BE: Potential use
of STAT3 inhibitors in targeted prostate cancer therapy: future
prospects. Oncol Targets Ther. 5:119–125. 2012.PubMed/NCBI
|
|
14
|
Flowers LO, Subramaniam PS and Johnson HM:
A SOCS-1 peptide mimetic inhibits both constitutive and IL-6
induced activation of STAT3 in prostate cancer cells. Oncogene.
24:2114–2120. 2005. View Article : Google Scholar
|
|
15
|
Klampfer L: Signal transducers and
activators of transcription (STATs): Novel targets of
chemopreventive and chemotherapeutic drugs. Curr Cancer Drug
Targets. 6:107–121. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, et al: Constitutive Stat3 activity up-regulates VEGF
expression and tumor angiogenesis. Oncogene. 21:2000–2008. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang S: Regulation of metastases by
signal transducer and activator of transcription 3 signaling
pathway: clinical implications. Clin Cancer Res. 13:1362–1366.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Zhang D, Luan X, Xie G and Pan X:
Inhibition of the signal transducers and activators of
transcription (STAT) 3 signalling pathway by AG490 in laryngeal
carcinoma cells. J Int Med Res. 38:1673–1681. 2010. View Article : Google Scholar
|
|
20
|
Huang C, Yang G, Jiang T, Huang K, Cao J
and Qiu Z: Effects of IL-6 and AG490 on regulation of Stat3
signaling pathway and invasion of human pancreatic cancer cells in
vitro. J Exp Clin Cancer Res. 29:512010. View Article : Google Scholar
|
|
21
|
Azare J, Leslie K, Al-Ahmadie H, Gerald W,
Weinreb PH, Violette SM and Bromberg J: Constitutively activated
Stat3 induces tumorigenesis and enhances cell motility of prostate
epithelial cells through integrin beta 6. Mol Cell Biol.
27:4444–4453. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abdulghani J, Gu L, Dagvadorj A, Lutz J,
Leiby B, Bonuccelli G, et al: Stat3 promotes metastatic progression
of prostate cancer. Am J Pathol. 172:1717–1728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun M, Liu C, Nadiminty N, Lou W, Zhu Y,
Yang J, et al: Inhibition of Stat3 activation by sanguinarine
suppresses prostate cancer cell growth and invasion. Prostate.
72:82–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rojas A, Liu G, Coleman I, Nelson PS,
Zhang M, Dash R, et al: IL-6 promotes prostate tumorigenesis and
progression through autocrine cross-activation of IGF-IR. Oncogene.
30:2345–2355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siddiquee K, Zhang S, Guida WC, Blaskovich
MA, Greedy B, Lawrence HR, et al: Selective chemical probe
inhibitor of Stat3, identified through structure-based virtual
screening, induces antitumor activity. Proc Natl Acad Sci USA.
104:7391–7296. 2007. View Article : Google Scholar
|
|
26
|
Zhang X, Yue P, Fletcher S, Zhao W,
Gunning PT and Turkson J: A novel small-molecule disrupts Stat3 SH2
domain-phosphotyrosine interactions and Stat3-dependent tumor
processes. Biochem Pharmacol. 79:1398–1409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pang M, Ma L, Gong R, Tolbert E, Mao H,
Ponnusamy M, et al: A novel STAT3 inhibitor, S3I-201, attenuates
renal interstitial fibroblast activation and interstitial fibrosis
in obstructive nephropathy. Kidney Int. 78:257–268. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen SH, Murphy DA, Lassoued W, Thurston
G, Feldman MD and Lee WM: Activated STAT3 is a mediator and
biomarker of VEGF endothelial activation. Cancer Biol Ther.
7:1994–2003. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu Q, Briggs J, Park S, Niu G, Kortylewski
M, Zhang S, et al: Targeting Stat3 blocks both HIF-1 and VEGF
expression induced by multiple oncogenic growth signaling pathways.
Oncogene. 24:5552–5560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cantarella G, Risuglia N, Dell’eva R,
Lempereur L, Albini A, Pennisi G, et al: TRAIL inhibits
angiogenesis stimulated by VEGF expression in human glioblastoma
cells. Br J Cancer. 94:1428–1435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu H, Chen A, Guo F and Yuan L: A
short-hairpin RNA targeting osteopontin downregulates MMP-2 and
MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett.
295:27–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bhattacharya S, Ray RM and Johnson LR:
STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents
apoptosis in polyamine-depleted cells. Biochem J. 392:335–344.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang S, Zhau HE, Osunkoya AO, Iqbal S,
Yang X, Fan S, et al: Vascular endothelial growth factor regulates
myeloid cell leukemia-1 expression through neuropilin-1-dependent
activation of c-MET signaling in human prostate cancer cells. Mol
Cancer. 9:92010. View Article : Google Scholar
|
|
34
|
Fortmüller K, Alt K, Gierschner D, Wolf P,
Baum V, Freudenberg N, et al: Effective targeting of prostate
cancer by lymphocytes redirected by a PSMA×CD3 bispecific
single-chain diabody. Prostate. 71:588–596. 2011.PubMed/NCBI
|
|
35
|
Kristjansdottir K, Kim K, Choi JS, Horan
TC, Brard L, Moore RG and Singh RK: 7 Methyl indole ethyl
isothiocyanate causes ROS mediated apoptosis and cell cycle arrest
in endometrial cancer cells. Gynecol Oncol. 126:252–258. 2012.
View Article : Google Scholar
|
|
36
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar
|
|
37
|
Huang C, Huang R, Chang W, Jiang T, Huang
K, Cao J, et al: The expression and clinical significance of
pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma.
59:52–61. 2012. View Article : Google Scholar
|
|
38
|
Liu X, He Z, Li CH, Huang G, Ding C and
Liu H: Correlation analysis of JAK-STAT pathway components on
prognosis of patients with prostate cancer. Pathol Oncol Res.
18:17–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang T, Yan XB, Zhao JJ, Ye J, Jiang ZF,
Wu DR, et al: Gene associated with retinoid-interferon-induced
mortality-19 suppresses growth of lung adenocarcinoma tumor in
vitro and in vivo. Lung Cancer. 72:287–293. 2011. View Article : Google Scholar
|
|
40
|
Lavecchia A, Di Giovanni C and Novellino
E: STAT-3 inhibitors: state of the art and new horizons for cancer
treatment. Curr Med Chem. 18:2359–2375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Santer FR, Malinowska K, Culig Z and
Cavarretta IT: Interleukin-6 trans-signalling differentially
regulates proliferation, migration, adhesion and maspin expression
in human prostate cancer cells. Endocr Relat Cancer. 17:241–253.
2010. View Article : Google Scholar
|
|
42
|
Yu JH, Kim KH and Kim H: Suppression of
IL-1beta expression by the Jak 2 inhibitor AG490 in
cerulein-stimulated pancreatic acinar cells. Biochem Pharmacol.
72:1555–1562. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lanuti P, Bertagnolo V, Pierdomenico L,
Bascelli A, Santavenere E, Alinari L, et al: Enhancement of TRAIL
cytotoxicity by AG-490 in human ALL cells is characterized by
downregulation of cIAP-1 and cIAP-2 through inhibition of
Jak2/Stat3. Cell Res. 19:1079–1089. 2009. View Article : Google Scholar
|
|
44
|
Shu M, Zhou Y, Zhu W, Wu S, Zheng X and
Yan G: Activation of a pro-survival pathway IL-6/JAK2/STAT3
contributes to glial fibrillary acidic protein induction during the
cholera toxin-induced differentiation of C6 malignant glioma cells.
Mol Oncol. 5:265–272. 2011. View Article : Google Scholar
|
|
45
|
Lin L, Amin R, Gallicano GI, Glasgow E,
Jogunoori W, Jessup JM, et al: The STAT3 inhibitor NSC 74859 is
effective in hepatocellular cancers with disrupted TGF-beta
signaling. Oncogene. 28:961–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen W, Shen X, Xia X, Xu G, Ma T, Bai X,
et al: NSC 74859-mediated inhibition of STAT3 enhances the
anti-proliferative activity of cetuximab in hepatocellular
carcinoma. Liver Int. 32:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin L, Hutzen B, Li PK, Ball S, Zuo M,
DeAngelis S, et al: A novel small molecule, LLL12, inhibits STAT3
phosphorylation and activities and exhibits potent
growth-suppressive activity in human cancer cells. Neoplasia.
12:39–50. 2010.
|
|
48
|
Epling-Burnette PK, Liu JH,
Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al:
Inhibition of STAT3 signaling leads to apoptosis of leukemic large
granular lymphocytes and decreased Mcl-1 expression. J Clin Invest.
107:351–362. 2001. View Article : Google Scholar
|
|
49
|
Kitagawa Y, Dai J, Zhang J, Keller JM, Nor
J, Yao Z, et al: Vascular endothelial growth factor contributes to
prostate cancer- mediated osteoblastic activity. Cancer Res.
65:10921–10929. 2005. View Article : Google Scholar
|
|
50
|
Huang W, Yu LF, Zhong J, Wu W, Zhu JY,
Jiang FX and Wu YL: Stat3 is involved in angiotensin II-induced
expression of MMP2 in gastric cancer cells. Dig Dis Sci.
54:2056–2062. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kang J, Bu J, Hao Y and Chen F: Subtoxic
concentration of doxorubicin enhances TRAIL-induced apoptosis in
human prostate cancer cell line LNCaP. Prostate Cancer Prostatic
Dis. 8:274–279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nesterov A, Lu X, Johnson M, Miller GJ,
Ivashchenko Y and Kraft AS: Elevated AKT activity protects the
prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J
Biol Chem. 276:10767–10774. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Horndasch M and Culig Z: SOCS-3
antagonizes pro-apoptotic effects of TRAIL and resveratrol in
prostate cancer cells. Prostate. 71:1357–1366. 2011.
|
